Michael Jäger Selected Research

2019-nCoV Vaccine mRNA-1273

7/2023	Virus-Subtype-Specific Cellular and Humoral Immune Response to a COVID-19 mRNA Vaccine in Chronic Kidney Disease Patients and Renal Transplant Recipients.
1/2023	Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
1/2022	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Jäger Research Topics

Disease

11	Neoplasms (Cancer) 01/2012 - 02/2004
7	Ascites 06/2012 - 11/2005
3	COVID-19 07/2023 - 01/2022
3	Infections 01/2023 - 01/2023
3	Peritoneal Neoplasms 01/2011 - 11/2005
3	Ovarian Neoplasms (Ovarian Cancer) 02/2009 - 07/2007
2	Convalescence 01/2023 - 01/2023
2	Fever (Fevers) 01/2011 - 02/2009
2	Bites and Stings (Sting) 01/2010 - 11/2008
2	Breast Neoplasms (Breast Cancer) 05/2009 - 05/2006
1	Chronic Renal Insufficiency 07/2023
1	Vasculitis (Vasculitides) 07/2023
1	Inflammation (Inflammations) 01/2023
1	Disease Progression 01/2023
1	Breakthrough Infections 01/2023
1	Atopic Dermatitis (Atopic Eczema) 03/2021
1	Pruritus (Itching) 03/2021
1	Carcinoma (Carcinomatosis) 01/2012
1	Vomiting 01/2011
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2011
1	Abdominal Pain (Pain, Abdominal) 01/2011
1	Nausea 02/2009
1	Malignant Pleural Effusion 02/2009
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2007
1	Lymphopenia (Lymphocytopenia) 05/2006
1	Melanoma (Melanoma, Malignant) 02/2004

Drug/Important Bio-Agent (IBA)

7	Epithelial Cell Adhesion MoleculeIBA 06/2012 - 11/2005
7	catumaxomabIBA 06/2012 - 07/2007
5	AntibodiesIBA 01/2022 - 02/2004
4	AntigensIBA 05/2009 - 02/2004
3	2019-nCoV Vaccine mRNA-1273IBA 07/2023 - 01/2022
3	BNT162 VaccineIBA 01/2023 - 01/2022
3	Monoclonal AntibodiesIBA 01/2023 - 10/2007
2	VaccinesIBA 07/2023 - 01/2023
2	N-(2-cyanoethylene)urea (BA 1)IBA 01/2023 - 01/2023
2	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2023 - 01/2023
2	CytokinesIBA 01/2012 - 02/2004
2	LigandsIBA 01/2010 - 11/2008
2	ertumaxomabIBA 05/2009 - 05/2006
2	EnzymesIBA 02/2009 - 05/2006
1	mRNA VaccinesIBA 07/2023
1	tixagevimabIBA 01/2023
1	cilgavimabIBA 01/2023
1	sotrovimabIBA 01/2023
1	COVID-19 VaccinesIBA 01/2023
1	Antiviral Agents (Antivirals)IBA 01/2023
1	Complement C3 (C3 Complement)IBA 01/2023
1	Neutralizing AntibodiesIBA 01/2023
1	regdanvimabIBA 01/2023
1	SARS-CoV-2 spike proteinIBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2012
1	MetalsIBA 01/2010
1	human ERBB2 proteinIBA 05/2009
1	Trastuzumab (Herceptin)FDA Link 05/2009
1	Immunoglobulins (Immunoglobulin)IBA 02/2009
1	GangliosidesIBA 02/2004
1	PerforinIBA 02/2004
1	Proteoglycans (Proteoglycan)IBA 02/2004

Therapy/Procedure

4	Therapeutics 01/2012 - 02/2004
3	Immunotherapy 01/2011 - 11/2005
2	Aftercare (After-Treatment) 01/2012 - 02/2009
1	Baths 03/2021
1	Drug Therapy (Chemotherapy) 02/2009